Highest-materiality recent filing
VivoSim gets Nasdaq delisting notice for bid price; proposes 1:5-1:20 reverse split
Nasdaq notice on Aug 17, 2026: VIVS closing bid below $1 for 30 consecutive sessions.
VivoSim regains Nasdaq equity compliance; cash $10.1M; guides 500%+ revenue growth in FY2027
Regained Nasdaq compliance (Rule 5550(b)(1)) after $5M Eli Lilly milestone and $4M financing.
VivoSim Labs receives Nasdaq delisting notice; subsequent transactions restore equity above $2.5M
Received Nasdaq delisting notice on July 20, 2026 for failing to maintain $2.5M minimum stockholders' equity; equity was $(1,099,000) as of March 31, 2026.
VivoSim prices up to $4M public offering, closes initial $3M tranche
Initial closing raised $3M at $1.14/share; 286,557 shares + 2,345,022 pre-funded warrants sold.
VivoSim Labs appoints Tony Lialin as Chief Commercial Officer
Tony Lialin appointed CCO effective Aug 11, 2025; leads go-to-market strategy for NAMkind liver/intestine 3D models.
VivoSim Labs regains compliance with Nasdaq minimum equity and bid price rules
On April 30, 2025, Nasdaq confirmed VivoSim Labs demonstrated compliance with minimum $2.5M stockholders' equity and $1.00 bid price requirements.
Effective April 24, 2025, Organovo Holdings changed its name to VivoSim Labs, Inc. with new ticker symbol VIVS on Nasdaq.
Organovo closes FXR program sale to Lilly; expects reduced spend and runway into FY2026
FXR program sold to Lilly; upfront payments received with future milestone payments anticipated.
Organovo closes sale of FXR program to Lilly for $10M upfront plus up to $50M milestones
Sale of FXR program including lead asset FXR314 to Eli Lilly completed on March 25, 2025.
Organovo implements 1-for-12 reverse stock split to regain Nasdaq minimum bid price compliance
Reverse stock split at ratio 1-for-12, effective March 20, 2025, to combine every 12 shares into 1.
Organovo sells FXR program to Eli Lilly for $10M upfront; faces Nasdaq delisting
Lilly to buy Organovo's FXR program for $10M upfront ($9M at close, $1M escrow) + up to $50M in milestones.
Nasdaq notified Organovo on Jan 16, 2025 that it failed to regain compliance with $1 minimum bid price rule.
Organovo names Norman Staskey President and CFO; Tomas Hess resigns for retirement
Tomas Hess resigned as President, CFO effective Dec 24, 2024 to pursue retirement; no disagreement on accounting policies.
Organovo shareholders approve reverse stock split (1:5-1:20) and 1.78M share equity plan increase
Reverse stock split authorized at ratio 1-to-5 to 1-to-20, board discretion until Nov 20, 2025; 88.64% voted for.
Organovo received Nasdaq delisting notice for bid price below $1 per share
Nasdaq notice on July 18, 2024: closing bid price below $1 for 30 consecutive business days.
Organovo prices $5.25M public offering of common stock and warrants
Offering of 6.56M units at $0.80/unit; gross proceeds $5.25M before expenses.
Organovo issues 1.35M shares for ~$1.8M under ATM facility
Issued 1,349,778 shares between Feb 1 and Apr 19, 2024; gross proceeds of $1.8 million.
Organovo cuts 24% of workforce; estimates $0.5M severance costs, $1.5M annual savings
Workforce reduction of ~6 employees (24% of staff) effective August 25, 2023.
Organovo reduces workforce by 24% and terminates General Counsel and CSO to focus on FXR314
Workforce reduced by ~6 employees (~24% of staff) effective Aug 25, 2023 to focus on clinical drug FXR314.
Organovo settles patent disputes with BICO; receives $1.5M upfront and ongoing royalties
BICO will pay Organovo $1.5M upfront plus ongoing low-to-high single-digit % royalties on net sales of licensed products.
Organovo CFO Jonathan Lieber resigns; Thomas P. Hess appointed as President and CFO
Jonathan Lieber resigned effective Oct 6, 2021, to pursue a full-time opportunity; no disagreement with the Company.
On March 21, 2025, Vaidehi Joshi notified the Board of Directors (the "Board") of the Company that she resigned from the Board and all committees of the Board, effective as of March 21, 2025.
Jeffrey Miner, Ph.D., the Company’s former Chief Scientific Officer, was notified that his employment with the Company would be terminated. Dr. Miner’s last day of employment was August 25, 2023.
Tom Jurgensen, the former General Counsel and Corporate Secretary of the Company, was notified that his employment with the Company would be terminated.
on August 16, 2023, Tom Jurgensen, the Company’s General Counsel and Corporate Secretary, and Jeffrey Miner, the Company’s Chief Scientific Officer, were each notified that his employment with the Company would be terminated.
on August 16, 2023, Tom Jurgensen, the Company’s General Counsel and Corporate Secretary, and Jeffrey Miner, the Company’s Chief Scientific Officer, were each notified that his employment with the Company would be terminated.
Effective March 8, 2022, the Board of Directors (the “Board”) of Organovo Holdings, Inc. (the “Company”) appointed Vaidehi Joshi to the Board as Class I Director.
On October 6, 2021, the Company’s Board of Directors appointed Thomas P. Hess, age 57, as the Company’s newly appointed President, Chief Financial Officer and Principal Financial Officer, effective October 6, 2021, in connection with the resignation of Mr. Lieber.
On October 6, 2021, Jonathan Lieber, the President, Chief Financial Officer and Principal Financial Officer of Organovo Holdings, Inc. (the “Company”), notified the Company of his intent to resign, effective October 6, 2021, from his part-time role to pursue a full-time opportunity.
Max materiality 0.80 · Median 0.55 · Most common event other_material